Acta Cytol

1. HOSHINO A, Oana Y, Ohi Y, Maeda Y, et al
   Using the DNA Integrity Number to Analyze DNA Quality in Specimens Collected from Liquid-Based Cytology after Fine-Needle Aspiration of Breast Tumors and Lesions.
   Acta Cytol. 2024;68:145-152.
   

   >> Share

   
   

   
   Ann Surg Oncol

2. NG TP, Loo BYK, Yong N, Chia CLK, et al
   ASO Visual Abstract: Implant-Based Breast Reconstruction After Mastectomy for Breast Cancer: A Meta-analysis of Randomised Controlled Trials and Prospective Studies Comparing Use of Acellular Dermal Matrix (ADM) Versus Without ADM.
   Ann Surg Oncol. 2024 May 23. doi: 10.1245/s10434-024-15446.
   

   >> Share

   
   
3. MYERS SP, Downs-Canner SM
   ASO Author Reflections: Immune-Related Adverse Events During Neoadjuvant Chemoimmunotherapy for Triple-Negative Breast Cancer May Influence Time to Adjuvant Radiation.
   Ann Surg Oncol. 2024 May 22. doi: 10.1245/s10434-024-15445.
   

   >> Share

   
   
4. MCINTOSH SA, Mactier M, Fairhurst K, Gath J, et al
   Understanding Patient Experiences to Inform Future Studies to Optimize Personalization of Treatment for Early Breast Cancer.
   Ann Surg Oncol. 2024 May 21. doi: 10.1245/s10434-024-15459.
   

   >> Share

   
   
5. ROACH EA, Weil CR, Cannon G, Grant J, et al
   ASO Visual Abstract: The Role of Axillary Lymph Node Dissection Versus Sentinel Lymph Node Dissection in Breast Cancer Patients with Clinical N2b-N3c Disease Who Receive Adjuvant Radiotherapy.
   Ann Surg Oncol. 2024 May 20. doi: 10.1245/s10434-024-15419.
   

   >> Share

   
   
6. MYERS SP, Sevilimedu V, Jones VM, Abuhadra N, et al
   Impact of Neoadjuvant Chemoimmunotherapy on Surgical Outcomes and Time to Radiation in Triple-Negative Breast Cancer.
   Ann Surg Oncol. 2024 May 20. doi: 10.1245/s10434-024-15359.
   

   >> Share

   
   

   
   BMC Cancer

7. YU S, Yue Z, Liu Q
   Pectinose induces cell cycle arrest in luminal A and triple-negative breast cancer cells by promoting autophagy through activation of the p38 MAPK signaling pathway.
   BMC Cancer. 2024;24:639.
   

   >> Share

   
   
8. KUEMMEL S, Harper-Wynne C, Park YH, Franke F, et al
   heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-po
   BMC Cancer. 2024;24:641.
   

   >> Share

   
   
9. LAMBERT V, Kane S, Howidi B, Nguyen BN, et al
   Systematic literature review of real-world evidence for treatments in HR+/HER2- second-line LABC/mBC after first-line treatment with CDK4/6i.
   BMC Cancer. 2024;24:631.
   

   >> Share

   
   
10. ZHENG M, Wu L, Xiao R, Cai J, et al
    Fbxo45 facilitates the malignant progression of breast cancer by targeting Bim for ubiquitination and degradation.
    BMC Cancer. 2024;24:619.
    

    >> Share

    
    
11. WANG Q, Chen H, Yang Q, Qiu J, et al
    Awareness and associated factors of venous thromboembolism in breast cancer surgical patients: a cross-sectional study.
    BMC Cancer. 2024;24:610.
    

    >> Share

    
    
12. EL HABRE R, Aoun R, Tahtouh R, Hilal G, et al
    All-trans-retinoic acid modulates glycolysis via H19 and telomerase: the role of mir-let-7a in estrogen receptor-positive breast cancer cells.
    BMC Cancer. 2024;24:615.
    

    >> Share

    
    

    
    Breast Cancer

13. FRANCESCHI BT, Bezerra PHA, Torqueti MR
    Antitumor effects of co-treatment of resveratrol with antitumor drugs in ER- and HER2-positive breast cancer cells are due to induction of apoptosis and modulation of estrogen receptor expression.
    Breast Cancer. 2024 May 23. doi: 10.1007/s12282-024-01590.
    

    >> Share

    
    
14. JEZEQUEL P, Lasla H, Gouraud W, Basseville A, et al
    Mesenchymal-like immune-altered is the fourth robust triple-negative breast cancer molecular subtype.
    Breast Cancer. 2024 May 22. doi: 10.1007/s12282-024-01597.
    

    >> Share

    
    
15. ALTUNDAG K
    Not all patients with premenopausal breast cancer will experience the negative effects of tamoxifen treatment on their bone mineral density.
    Breast Cancer. 2024 May 18. doi: 10.1007/s12282-024-01595.
    

    >> Share

    
    

    
    Breast Cancer (Auckl)

16. SEKAR AP, Nurmala S, Matsuura E, Tan XW, et al
    Estrogen Receptor Is Required for Metformin-Induced Apoptosis in Breast Cancer Cells Under Hyperglycemic Conditions.
    Breast Cancer (Auckl). 2024;18:11782234241240173.
    

    >> Share

    
    

    
    Breast Cancer Res

17. MAO H, Jin M, Xie L, Mao N, et al
    Infrared laser moxibustion for cancer-related fatigue in breast cancer survivors: a randomized controlled trial.
    Breast Cancer Res. 2024;26:80.
    

    >> Share

    
    
18. VAN CAUWENBERGE J, Van Baelen K, Maetens M, Geukens T, et al
    Reporting on patient's body mass index (BMI) in recent clinical trials for patients with breast cancer: a systematic review.
    Breast Cancer Res. 2024;26:81.
    

    >> Share

    
    
19. JACOBS SA, Wang Y, Abraham J, Feng H, et al
    Correction: NSABP FB-10: a phase Ib/II trial evaluating ado-trastuzumab emtansine (T-DM1) with neratinib in women with metastatic HER2-positive breast cancer.
    Breast Cancer Res. 2024;26:83.
    

    >> Share

    
    

    
    Breast Cancer Res Treat

20. SCHWIEGER L, Postlewait LM, Liu Y, Jou S, et al
    Changes in expression of breast cancer tumor biomarkers between primary tumors and corresponding metastatic sites: common patterns and relationships with survival.
    Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07368.
    

    >> Share

    
    
21. ZHUO X, Deng H, Qiu M, Qiu X, et al
    Pathomic model based on histopathological features and machine learning to predict IDO1 status and its association with breast cancer prognosis.
    Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07350.
    

    >> Share

    
    
22. PEARSON A, Chen J, Dhillon HM, Kiely BE, et al
    Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review.
    Breast Cancer Res Treat. 2024 May 23. doi: 10.1007/s10549-024-07364.
    

    >> Share

    
    
23. WHITE O, Dent S, Westbrook K, Lee HJ, et al
    Assessment of efficacy and safety of dose-dense doxorubicin and cyclophosphamide (ddAC) in combination with immunotherapy in early-stage triple-negative breast cancer.
    Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07354.
    

    >> Share

    
    
24. ZHANG Y, Wang H, Zhao H, He X, et al
    Prognostic significance and value of further classification of lymphovascular invasion in invasive breast cancer: a retrospective observational study.
    Breast Cancer Res Treat. 2024 May 21. doi: 10.1007/s10549-024-07318.
    

    >> Share

    
    
25. BARKUR S, Boitor RA, Mihai R, Gopal NSR, et al
    Intraoperative spectroscopic evaluation of sentinel lymph nodes in breast cancer surgery.
    Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07349.
    

    >> Share

    
    
26. GUPTA A, Roy AM, Gupta K, Attwood K, et al
    Impact of environmental temperature on the survival outcomes of breast cancer: A SEER-based study.
    Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07369.
    

    >> Share

    
    
27. BOLDRINI L, Dinapoli L, Boccia E, Caliandro M, et al
    Coping with modesty during radiotherapy for breast cancer: a multicentric study.
    Breast Cancer Res Treat. 2024 May 18. doi: 10.1007/s10549-024-07365.
    

    >> Share

    
    
28. STRELL C, Smith DR, Valachis A, Woldeyesus H, et al
    Use of beta-blockers in patients with ductal carcinoma in situ and risk of invasive breast cancer recurrence: a Swedish retrospective cohort study.
    Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07358.
    

    >> Share

    
    
29. COLE KM, McGee S, Clemons M, Liu M, et al
    Development and application of a weighted change score to evaluate interventions for vasomotor symptoms in patients with breast cancer using regression trees: a cohort study.
    Breast Cancer Res Treat. 2024 May 19. doi: 10.1007/s10549-024-07360.
    

    >> Share

    
    
30. TAKANO T, Masuda N, Ito M, Inoue K, et al
    Long-term outcomes of neoadjuvant trastuzumab emtansine + pertuzumab (T-DM1 + P) and docetaxel + carboplatin + trastuzumab + pertuzumab (TCbHP) for HER2-positive primary breast cancer: results of the randomized phase 2 JBCRG20 study (Neo-peaks).
    Breast Cancer Res Treat. 2024 May 20. doi: 10.1007/s10549-024-07333.
    

    >> Share

    
    

    
    Cancer Epidemiol Biomarkers Prev

31. YE Z, Nguyen TL, Dite GS, Maclnnis RJ, et al
    Mammographic texture versus conventional Cumulus measure of density in breast cancer risk prediction: a literature review.
    Cancer Epidemiol Biomarkers Prev. 2024.
    

    >> Share

    
    

    
    Cancer Lett

32. BELLI S, Esposito D, Ascione CM, Messina F, et al
    EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Cancer Lett. 2024 May 22:216968. doi: 10.1016/j.canlet.2024.216968.
    

    >> Share

    
    

    
    Clin Breast Cancer

33. MESA-CHAVEZ F, Chavarri-Guerra Y, Lopez-Covarrubias AV, Mayette-Villanueva AE, et al
    Multicenter Study on the Frequency of Low Bone Mineral Density in Young Women With Breast Cancer and Associated Factors.
    Clin Breast Cancer. 2024 May 3:S1526-8209(24)00112.
    

    >> Share

    
    

    
    Clin Cancer Res

34. CHEUNG A, Chenoweth AM, Johansson A, Laddach R, et al
    Anti-EGFR antibody-drug conjugate carrying an inhibitor targeting CDK restricts triple-negative breast cancer growth.
    Clin Cancer Res. 2024 May 21. doi: 10.1158/1078-0432.CCR-23-3110.
    

    >> Share

    
    

    
    Eur J Surg Oncol

35. SPOOR J, Heeling E, Collewijn RC, van der Ploeg IMC, et al
    Intraoperative frozen section of subareolar tissue in nipple-sparing mastectomy: Towards a less is more approach.
    Eur J Surg Oncol. 2024;50:108320.
    

    >> Share

    
    

    
    Eur Radiol

36. CHAE EY, Jung MR, Cha JH, Shin HJ, et al
    A predictive model using MRI and clinicopathologic features for breast cancer recurrence in young women treated with upfront surgery.
    Eur Radiol. 2024 May 24. doi: 10.1007/s00330-024-10805.
    

    >> Share

    
    

    
    J Biol Chem

37. DUAN L, Tadi MJ, O'Hara KM, Maki CG, et al
    Novel markers of MCL1 inhibitor sensitivity in triple negative breast cancer cells.
    J Biol Chem. 2024 May 16:107375. doi: 10.1016/j.jbc.2024.107375.
    

    >> Share

    
    

    
    J Clin Oncol

38. FREEDMAN RA, Caswell-Jin JL, Hassett M, Somerfield MR, et al
    Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer-Cyclin-Dependent Kinase 4 and 6 Inhibitors: ASCO Guideline Rapid Recommendation Update.
    J Clin Oncol. 2024 May 20:JCO2400886. doi: 10.1200/JCO.24.00886.
    

    >> Share

    
    
39. LU YS, Bin Mohd Mahidin EI, Azim H, Eralp Y, et al
    Final results of RIGHT Choice: Ribociclib plus endocrine therapy vs combination chemotherapy in premenopausal women with clinically aggressive HR+/HER2- advanced breast cancer.
    J Clin Oncol. 2024 May 21:JCO2400144. doi: 10.1200/JCO.24.00144.
    

    >> Share

    
    

    
    J Surg Oncol

40. DI PACE B, Padley RH
    Breast cancer survivorship: A viewpoint.
    J Surg Oncol. 2024 May 19. doi: 10.1002/jso.27680.
    

    >> Share

    
    

    
    Lancet

41. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

42. DIECI MV, Guarneri V
    Gaining ground in personalized breast cancer therapy: lesson learned from PHERGain.
    Nat Rev Clin Oncol. 2024 May 22. doi: 10.1038/s41571-024-00907.
    

    >> Share

    
    
43. KILLOCK D
    ALND can be safely omitted for patients with sentinel-node macrometastases.
    Nat Rev Clin Oncol. 2024;21:402.
    

    >> Share

    
    

    
    PLoS One

44. KHOIRUNNISA SM, Suryanegara FDA, Setiawan D, Postma MJ, et al
    Economic evaluation of trastuzumab in HER2-positive early breast cancer in Indonesia: A cost-effectiveness analysis.
    PLoS One. 2024;19:e0304483.
    

    >> Share

    
    
45. RAN T, Chen J, She Q, Mu Y, et al
    Anthracycline-induced arrhythmias in breast cancer therapy: A meta-analysis of single-arm trials.
    PLoS One. 2024;19:e0303208.
    

    >> Share

    
    
46. OKYERE ASANTE PG, Owusu AY, Oppong JR, Amegah KE, et al
    An assessment of the direct and indirect costs of breast cancer treatment in leading cancer hospitals in Ghana.
    PLoS One. 2024;19:e0301378.
    

    >> Share

    
    
47. JOHNSON KJ, O'Connell CP, Waken RJ, Barnes JM, et al
    Impact of COVID-19 pandemic on breast cancer screening in a large midwestern United States academic medical center.
    PLoS One. 2024;19:e0303280.
    

    >> Share

    
    

    
    Radiol Artif Intell

48. ELLIS S, Gomes S, Trumble M, Halling-Brown MD, et al
    Deep Learning for Breast Cancer Risk Prediction: Application to a Large Representative UK Screening Cohort.
    Radiol Artif Intell. 2024 May 22:e230431. doi: 10.1148/ryai.230431.
    

    >> Share

    
    

    
    Radiology

49. NGUYEN DL, Ren Y, Jones TM, Thomas SM, et al
    Patient Characteristics Impact Performance of AI Algorithm in Interpreting Negative Screening Digital Breast Tomosynthesis Studies.
    Radiology. 2024;311:e232286.
    

    >> Share

    
    
50. KATAOKA M, Iima M
    Potential of the Diffusion-based Noncontrast Protocol for Breast Imaging: Current Status and Hints for Improvements.
    Radiology. 2024;311:e241058.
    

    >> Share

    
    
51. POTSCH N, Sodano C, Baltzer PAT
    Performance of Diffusion-weighted Imaging-based Noncontrast MRI Protocols for Diagnosis of Breast Cancer: A Systematic Review and Meta-Analysis.
    Radiology. 2024;311:e232508.
    

    >> Share

    
    
52. TURKBEY B
    Use of Molecular Imaging to Further Investigate PI-RADS 3 Lesions.
    Radiology. 2024;311:e240401.
    

    >> Share

    
    

    
    Radiother Oncol

53. CHEN F, Zhou P, Ren G, Lee EKW, et al
    Interpretable deep learning insights: Unveiling the role of 1 Gy volume on lymphopenia after radiotherapy in breast cancer.
    Radiother Oncol. 2024;197:110333.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share